VSPharmTech
PrivateLast Round
Series C
Jun 1, 2026
Est. Valuation
$68.9M
Total Funding Raised
$14.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
VSPharmTech operates in Healthcare & Life Sciences and is based in Daegu. Its latest recorded funding round was a Series B Extension round in September 2025.
VSPharmTech is a biotechnology company that develops innovative radiosensitizer drugs designed to enhance the effectiveness of radiation therapy for various types of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VSPharmTech Comparables
Compare VSPharmTech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shuttle Pharmaceuticals Holdings, Inc. | 85% | |
| KORTUC INC. | 80% | |
| DNA Therapeutics | 79% |
For institutional investors. Book with your work email.
VSPharmTech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 1, 2026 | ||||
| Series B Extension | Sep 18, 2025 | ||||
| Series B | Oct 1, 2023 | ||||
| VC Round | Apr 11, 2023 | ||||
| Series A | Apr 8, 2022 | ||||
Seed | May 18, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
VSPharmTech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Y&Archer | Seed, Accelerator |
| SL Investment | Series B |
| IBK Capital | Series B |
| Kairos Ventures | VC Round |
| Korea Development Bank | Series B |
| ST Capital (Korea) | Series A |
| Enlight Ventures | Seed, Series B, VC Round, Series A, Series B Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 167% MoM, reaching 650.
- Jun 1, 2026
$40M round completed.
For institutional investors. Book with your work email.
VSPharmTech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VSPharmTech's valuation, stock price, and market status.
Is VSPharmTech a public or private company?
VSPharmTech is a private company.
What is the current stock price of VSPharmTech?
VSPharmTech is a private company, so its shares have no public market price. Caplight tracks VSPharmTech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VSPharmTech worth (valuation)?
VSPharmTech's valuation is estimated at $68.9M based on funding round data.
Can I buy VSPharmTech stock?
VSPharmTech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VSPharmTech's last funding round?
VSPharmTech's most recent funding round was Series C on June 1, 2026.
Who are the main investors in VSPharmTech?
Key investors in VSPharmTech include SL Investment, IBK Capital, Korea Development Bank, Enlight Ventures, JCH Investment.
Will VSPharmTech IPO soon?
No public IPO plans have been announced for VSPharmTech.
How can I track VSPharmTech secondary market activity?
Caplight tracks bids, offers, and trades in VSPharmTech's shares on secondary markets.